Icon Créer jeu Créer jeu
Obtenir Plan Académique
Obtenir Plan Académique
Obtenir Plan Académique

Infection, Tumor imaging, and Therapy Review Test (1/3)

Test

T/F questions

Téléchargez la version pour jouer sur papier

Âge recommandé: 16 ans
11 fois fait

Créé par

United States

Top 10 résultats

  1. 1
    02:16
    temps
    100
    but
Voulez-vous apparaître dans le Top 10 de ce jeu? pour vous identifier.
Créez votre propre jeu gratuite à partir de notre créateur de jeu
Affrontez vos amis pour voir qui obtient le meilleur score dans ce jeu

Top Jeux

  1. temps
    but
  1. temps
    but
temps
but
temps
but
 
game-icon

Infection, Tumor imaging, and Therapy Review Test (1/3)Version en ligne

T/F questions

par Joshua Liberty
1

I-125 has Tp of 35.5 days; it decays by EC; it has 27.4 and 31 KeV x-rays and a 60 KeV gamma.

2

Y-90 labeled glass microspheres is being used; the formula for dose calculation is; Activ required in GBq=(liver mass in Kg/ Desired dose in Gys)/50.

3

Tilmanocept is DTPA-mannosyl-dextran, a macromolecule with an average diameter of between 100 and 220 nm

4

Tilmanocept may be administered to a patient as a single injection or as multiple injections.

5

Smaller particles are generally recommended in lymphoscintigraphy as more frequent visualization of lymphatic channels is activated.

6

With lymphoscintigraphy for melanoma, imaging begins immediately after injection and is repeated at 5 minute intervals for 45 to 60 minutes.

7

Usual dose for Ga-67 Citrate is 5-10 mCi.

8

With Ga-67 Citrate, the reason for delayed views is concentration in tissue is stable while blood clearance improves over time.

9

With In-111 Oxine labeled WBCs, early lung activity occurs, then clears out.

10

With In-111 Oxine labeled WBCs, uptake in liver and spleen is abnormal.

11

Leukocyte agents are nonspecific and also localize in areas of inflammation, without infection.

12

Sestamibi Breast imaging should be delayed 2 weeks following FNA and 4-6 weeks post core biopsy.

13

The main disadvantage with Tc99m HMPAO WBC imaging is the tag to WBCs begins to breakdown leading to renal and GI excretion-this complicates GI infection localization.

14

Use of Y-90 labeled Glass Microspheres is contradicted in patients whose Tc99m MAA hepatic arterial perfusion scintigraphy shows any deposition to the GI tract that may not be corrected by angiographic techniques.

15

A tech cannot find a vein on a In-111 WBC patient; he can try using a 25g needle with no effect on scan.

16

Both benign and malignant conditions can result in lung nodules.

17

Patient should have no strenuous activity for 24 hours before PET/FDG scan.

18

Ideal patient blood glucose is 200mg/dl before FDG scan?

19

The most common adult FDG dose is 10 mCi.

20

ROCM enhancement occurs because it lets more photons through.

21

Total body PET FDG scanning is ideal for malignant melanoma and sarcoma patients.

22

In PET/CT, acquiring images with patients arms to the side would increase beam hardening and truncate CT data.

23

Gliomas are the most common brain tumors.

24

PET FDG is better than bone scans for prostate cancer mets.

25

Obese patients have lower SUVs for both normal and malignant tissue.

26

Due to partial volume effects , SUV of lesions smaller than the spatial resolution of the scanner will be overestimated.

27

I-125 seeds are indicated for permanent interstitial treatment of selected localized tumors such as ;head and neck, lung, pancreas, and early stage prostate.

28

Fluciclovine F-18 uptake is not specific for prostate cancer and may occur with other types of cancer and benign prostatic hypertrophy in primary prostate cancer.

29

Before initiating Lu-177 Dotatate; Discontinue long-acting somatostatin analogs (E.g. long-acting octreotide) for at least 4 weeks prior to initiating therapy. Administer short-acting octreotide as needed; discontinue at least 24 hours prior to initiating therapy.

30

Secondary brain tumors are more prevalent in the pediatric population while adults are more prone to experience primary brain tumors.

educaplay suscripción